Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
about
Adoptive T Cell Therapy Targeting CD1 and MR1Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationT cell engineering as therapy for cancer and HIV: our synthetic futureBET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy modelsCreation of an engineered APC system to explore and optimize the presentation of immunodominant peptides of major allergensTowards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells.Specific roles of each TCR hemichain in generating functional chain-centric TCR.Mouse and Human CD1d-Self-Lipid Complexes Are Recognized Differently by Murine Invariant Natural Killer T Cell ReceptorsCo-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.CDR3β sequence motifs regulate autoreactivity of human invariant NKT cell receptors.Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses.Engineering T cells for cancer: our synthetic future.Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptorsEngineered Materials for Cancer Immunotherapy.Paracrine release of IL-2 and anti-CTLA-4 enhances the ability of artificial polymer antigen-presenting cells to expand antigen-specific T cells and inhibit tumor growth in a mouse model.Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer ImmunotherapiesHLA-DP84Gly constitutively presents endogenous peptides generated by the class I antigen processing pathway.A Subset of Human Autoreactive CD1c-Restricted T Cells Preferentially Expresses TRBV4-1+ TCRs.Immunoengineering with biomaterials for enhanced cancer immunotherapy.A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication.Mechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP84Gly.Nanoscale artificial antigen presenting cells for cancer immunotherapy.Integrating Immunology and Microfluidics for Single Immune Cell Analysis
P2860
Q26998503-595CD91D-A87C-4DEB-9648-3A4966B2BC62Q28068378-7402D349-6D21-4789-9A6A-07BAB458C106Q28082253-003C1774-153B-4F2E-867E-64D3302B567CQ28828457-0EEC371F-405B-4332-B3BA-FEE85A7DF032Q28829665-352DE6C5-C53B-409A-A747-6DD76E4BE681Q34428078-6DE46C92-2F07-42DE-A9D4-1E3334226A79Q35205495-3856DE03-BF50-4F7E-89C2-E19A1CB3BABFQ36026142-46F3236D-D313-48BC-B654-573F3224C55CQ36123941-1F304180-1235-4841-A417-0866A2600D97Q36689593-136E90B3-9E5B-444A-A471-B56A3033044DQ37109545-C2131C31-18D0-4C8F-B10B-4EC4FE111C41Q37419985-2D30E47B-8F8E-40B4-A01E-2C80F9708EDAQ37515502-9F3717EC-89D0-4C4D-BBC3-F34A03831CF0Q38291751-A387DBA8-4700-47E4-9D21-CBCB525FF906Q38660577-5305E73E-567E-4FAB-B285-AE4AC7426833Q38684217-46AE8430-5BC4-4943-BDF5-53BAAF0563EAQ41257879-79AB07F0-E9D8-4F7A-96B3-B2E0E055B15FQ41442041-A9E49D84-73E2-4C83-80EB-1C1974DE3950Q41988716-64738082-8463-4870-80E4-19CDF2157470Q47296458-BAD59412-5DF3-4B84-BA79-6280F952D00FQ47732542-21DB2B03-6347-488C-BE39-5EFD85A7CCBAQ48184244-6C16763A-442A-4400-BBEA-51A6B1B1B047Q52349756-0AECA550-6E1E-4067-B1E1-DD533ADC9AF9Q52662884-49F80F72-6605-44E2-9F34-8FF142130791Q59136363-C9C1E2C0-76F6-4EAC-9D00-3EA4994D0DF5
P2860
Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
@ast
Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
@en
Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
@nl
type
label
Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
@ast
Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
@en
Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
@nl
prefLabel
Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
@ast
Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
@en
Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
@nl
P2860
P356
P1476
Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
@en
P2093
Naoto Hirano
P2860
P304
P356
10.1111/IMR.12129
P577
2014-01-01T00:00:00Z